S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
S&P 500   4,584.49 (+1.58%)
DOW   34,688.52 (+1.96%)
QQQ   389.66 (+0.66%)
AAPL   163.13 (-1.00%)
MSFT   330.76 (+0.21%)
FB   308.90 (-0.55%)
GOOGL   2,864.00 (+1.52%)
AMZN   3,441.64 (-0.06%)
TSLA   1,079.24 (-1.44%)
NVDA   321.34 (+2.22%)
BABA   121.09 (-1.14%)
NIO   35.33 (-7.78%)
CGC   9.95 (+0.10%)
AMD   150.18 (+0.72%)
GE   95.01 (+2.16%)
MU   83.11 (-2.40%)
T   23.11 (+3.96%)
F   19.81 (+1.17%)
DIS   146.39 (+2.98%)
PFE   53.61 (-1.96%)
AMC   29.37 (+2.80%)
ACB   5.95 (-1.00%)
BA   198.45 (+5.45%)
NYSE:AVNS

Avanos Medical Stock Forecast, Price & News

$30.20
+0.52 (+1.75%)
(As of 12/2/2021 01:38 PM ET)
Add
Compare
Today's Range
$29.20
$30.29
50-Day Range
$29.68
$36.02
52-Week Range
$29.63
$53.61
Volume
4,019 shs
Average Volume
341,529 shs
Market Capitalization
$1.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.87
30 days | 90 days | 365 days | Advanced Chart
Receive AVNS News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.


Avanos Medical logo

About Avanos Medical

Avanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm's portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
5,300
Year Founded
N/A

Sales & Book Value

Annual Sales
$714.80 million
Cash Flow
$1.64 per share
Book Value
$26.27 per share

Profitability

Net Income
$-27.20 million
Pretax Margin
-8.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
47,710,000
Market Cap
$1.46 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/17/2022

MarketRank

Overall MarketRank

2.41 out of 5 stars

Medical Sector

175th out of 1,391 stocks

Surgical Appliances & Supplies Industry

6th out of 27 stocks

Analyst Opinion: 3.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -












Avanos Medical (NYSE:AVNS) Frequently Asked Questions

Is Avanos Medical a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Avanos Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View analyst ratings for Avanos Medical
or view top-rated stocks.

How has Avanos Medical's stock price been impacted by Coronavirus (COVID-19)?

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AVNS shares have increased by 4.1% and is now trading at $30.20.
View which stocks have been most impacted by COVID-19
.

When is Avanos Medical's next earnings date?

Avanos Medical is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for Avanos Medical
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported $0.25 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.27 by $0.02. Avanos Medical had a positive trailing twelve-month return on equity of 3.67% and a negative net margin of 7.06%. During the same quarter last year, the company posted $0.21 EPS.
View Avanos Medical's earnings history
.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $1.100-$1.200 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.140. The company issued revenue guidance of -.

What price target have analysts set for AVNS?

3 analysts have issued 12 month target prices for Avanos Medical's stock. Their forecasts range from $41.00 to $47.00. On average, they expect Avanos Medical's share price to reach $44.33 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts' price targets for Avanos Medical
or view top-rated stocks among Wall Street analysts.

Who are Avanos Medical's key executives?

Avanos Medical's management team includes the following people:
  • Joseph F. Woody, Chief Executive Officer & Executive Director
  • Michael C. Greiner, CFO, Chief Accounting Officer & Senior VP
  • Lee Burnes, Senior VP-Global Research & Development
  • Michelle Scharfenberg, Senior VP, Chief Ethics & Compliance Officer
  • Rhonda D. Gibby, Chief Human Resources Officer & Senior VP

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical CEO Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among Avanos Medical's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Honeywell International (HON), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.14%), Paradice Investment Management LLC (6.42%), Dimensional Fund Advisors LP (4.51%), Macquarie Group Ltd. (3.58%), Goldman Sachs Group Inc. (2.98%) and Geode Capital Management LLC (1.68%). Company insiders that own Avanos Medical stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends for Avanos Medical
.

Which major investors are selling Avanos Medical stock?

AVNS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Dimensional Fund Advisors LP, Morgan Stanley, BlackRock Inc., Deutsche Bank AG, Goldman Sachs Group Inc., Maverick Capital Ltd., and Principal Financial Group Inc..
View insider buying and selling activity for Avanos Medical
or view top insider-selling stocks.

Which major investors are buying Avanos Medical stock?

AVNS stock was acquired by a variety of institutional investors in the last quarter, including Paradice Investment Management LLC, Neuberger Berman Group LLC, Balyasny Asset Management LLC, Tributary Capital Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Eagle Asset Management Inc., and Macquarie Group Ltd.. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, and Patrick J Oleary.
View insider buying and selling activity for Avanos Medical
or or view top insider-buying stocks.

How do I buy shares of Avanos Medical?

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $30.20.

How much money does Avanos Medical make?

Avanos Medical has a market capitalization of $1.46 billion and generates $714.80 million in revenue each year. The company earns $-27.20 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Avanos Medical have?

Avanos Medical employs 5,300 workers across the globe.

What is Avanos Medical's official website?

The official website for Avanos Medical is avanos.com.

Where are Avanos Medical's headquarters?

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at (844) 428-2667 or via email at [email protected].


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.